Lipella Pharmaceuticals (LIPO) Competitors $0.60 +0.01 (+1.69%) As of 01:13 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LIPO vs. PHXM, SNSE, ERNA, INAB, APM, TRAW, CSCI, KPRX, PCSA, and DWTXShould you be buying Lipella Pharmaceuticals stock or one of its competitors? The main competitors of Lipella Pharmaceuticals include PHAXIAM Therapeutics (PHXM), Sensei Biotherapeutics (SNSE), Ernexa Therapeutics (ERNA), IN8bio (INAB), Aptorum Group (APM), Traws Pharma (TRAW), COSCIENS Biopharma (CSCI), Kiora Pharmaceuticals (KPRX), Heatwurx (PCSA), and Dogwood Therapeutics (DWTX). These companies are all part of the "pharmaceutical products" industry. Lipella Pharmaceuticals vs. Its Competitors PHAXIAM Therapeutics Sensei Biotherapeutics Ernexa Therapeutics IN8bio Aptorum Group Traws Pharma COSCIENS Biopharma Kiora Pharmaceuticals Heatwurx Dogwood Therapeutics Lipella Pharmaceuticals (NASDAQ:LIPO) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk. Is LIPO or PHXM more profitable? PHAXIAM Therapeutics has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. PHAXIAM Therapeutics' return on equity of 0.00% beat Lipella Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Lipella Pharmaceuticals-988.83% -224.08% -172.88% PHAXIAM Therapeutics N/A N/A N/A Does the media favor LIPO or PHXM? In the previous week, Lipella Pharmaceuticals had 1 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 1 mentions for Lipella Pharmaceuticals and 0 mentions for PHAXIAM Therapeutics. PHAXIAM Therapeutics' average media sentiment score of 0.00 beat Lipella Pharmaceuticals' score of -1.00 indicating that PHAXIAM Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Lipella Pharmaceuticals Negative PHAXIAM Therapeutics Neutral Which has more risk & volatility, LIPO or PHXM? Lipella Pharmaceuticals has a beta of -0.1, suggesting that its share price is 110% less volatile than the S&P 500. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, suggesting that its share price is 135% more volatile than the S&P 500. Which has higher valuation & earnings, LIPO or PHXM? PHAXIAM Therapeutics has lower revenue, but higher earnings than Lipella Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLipella Pharmaceuticals$536.36K5.18-$5.02M-$3.43-0.18PHAXIAM TherapeuticsN/AN/A-$240KN/AN/A Do institutionals and insiders believe in LIPO or PHXM? 74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. 32.1% of Lipella Pharmaceuticals shares are owned by company insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryPHAXIAM Therapeutics beats Lipella Pharmaceuticals on 6 of the 10 factors compared between the two stocks. Get Lipella Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LIPO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LIPO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIPO vs. The Competition Export to ExcelMetricLipella PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.73M$3.12B$5.77B$9.92BDividend YieldN/A2.29%6.71%4.51%P/E Ratio-0.157.5556.5522.02Price / Sales5.18466.49534.30112.03Price / CashN/A44.9736.9659.01Price / Book0.389.8611.446.09Net Income-$5.02M-$53.47M$3.28B$266.14M7 Day Performance1.85%2.89%0.84%0.28%1 Month Performance-7.54%8.62%7.15%4.14%1 Year Performance-81.45%13.69%59.66%23.93% Lipella Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIPOLipella Pharmaceuticals0.8884 of 5 stars$0.60+1.7%N/A-82.3%$2.73M$536.36K-0.154Negative NewsShort Interest ↑PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049SNSESensei Biotherapeutics4.356 of 5 stars$8.23-1.4%$55.00+568.3%-27.3%$10.38MN/A-0.3940Short Interest ↑ERNAErnexa Therapeutics1.0111 of 5 stars$1.35+1.4%N/A-95.3%$10.34M$580K-0.1610Positive NewsShort Interest ↓Gap UpINABIN8bio3.7913 of 5 stars$2.22+0.2%$180.00+8,026.4%-84.9%$10.06MN/A-0.2420Positive NewsShort Interest ↓APMAptorum Group2.1722 of 5 stars$1.87-5.1%N/A-39.3%$10.00M$430K0.0030News CoverageShort Interest ↓Gap DownTRAWTraws Pharma0.7351 of 5 stars$1.41+0.7%N/AN/A$9.96M$230K0.0217Short Interest ↑CSCICOSCIENS BiopharmaN/A$3.10+1.9%N/A-32.4%$9.86M$9.59M-0.5220Positive NewsKPRXKiora Pharmaceuticals3.1622 of 5 stars$2.76-0.8%$10.00+262.5%-22.2%$9.47MN/A-0.9510Positive NewsAnalyst ForecastAnalyst RevisionPCSAHeatwurx3.2431 of 5 stars$0.19-1.1%$1.00+434.8%-87.8%$9.42MN/A-0.0820News CoverageAnalyst ForecastShort Interest ↑Analyst RevisionDWTXDogwood Therapeutics1.3159 of 5 stars$4.89-1.3%$10.00+104.3%N/A$9.35MN/A-0.265 Related Companies and Tools Related Companies PHXM Competitors SNSE Competitors ERNA Competitors INAB Competitors APM Competitors TRAW Competitors CSCI Competitors KPRX Competitors PCSA Competitors DWTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LIPO) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipella Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipella Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
